- Advertisement -spot_img
28.2 C
HomeCompany NewsBritain's health regulator approves GSK's vaccine for common respiratory virus

Britain’s health regulator approves GSK’s vaccine for common respiratory virus

- Advertisement -spot_img

Britain’s health regulator approved GSK’s vaccine for the respiratory syncytial virus (RSV), which causes thousands of hospitalisations and deaths annually, the drugmaker said on Monday.

The Medicines and Healthcare products Regulatory Agency (MHRA) authorised GSK’s shot, called Arexvy, for active immunisation to prevent lower respiratory tract disease caused by RSV in adults 60 years and older, the company said.

READ ALSO:  Nigeria records $1.13 bln Capital Inflows in Q1 2023, down 28% vs Q1 2022

RSV typically causes cold-like symptoms but is a leading cause of pneumonia in toddlers and the elderly.

The complex molecular structure of the virus and safety concerns with previous vaccine attempts had stymied efforts to successfully develop a shot since the virus was first discovered in 1956.

Arexvy has recently got the green light from the United States and European regulators.

Join Our Mailing List!

* indicates required
- Advertisement -spot_img
- Advertisement -spot_img
Must Read
Related News
- Advertisement -spot_img